SCHEMBL12876343

SCHEMBL12876343

COC(=O)c1cnn(Cc2nc(-c3cccc(C)c3)cs2)c1C1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SIRT5 Q9NXA8 2/20 0.40
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 2/20 0.37
NAMPT P43490 1/20 0.37
GRIN2B Q13224 1/20 0.36
AKT1 P31749 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876353 0.90 NFE2L2 (0.42) SIRT5ITGB3ITGA2BKDM4EALDH1A1
SCHEMBL1198790 0.88 ITGB2 (0.45) SIRT5ITGB3ITGA2BKDM4EHPGD
SCHEMBL12875696 0.79 KMT2A (0.53) NPC1RAB9AITGB3ITGA2BKDM4E
SCHEMBL12875697 0.78 SIRT5 (0.44) SIRT5ITGB3ITGA2BKDM4EHPGD
SCHEMBL1198344 0.77 KDM4E (0.47) SIRT5ITGB3ITGA2BKDM4EALDH1A1
SCHEMBL1198469 0.70 KDM4E (0.44) KDM4EHPGDGAAL3MBTL1ALDH1A1
SCHEMBL12876862 0.70 LTA4H (0.41) RAB9ASIRT5KDM4EHPGDL3MBTL1
SCHEMBL12875688 0.70 L3MBTL1 (0.47) KDM4EHPGDGAAL3MBTL1ALDH1A1
SCHEMBL12876765 0.70 SIRT5 (0.52) SIRT5KDM4EALDH1A1MAPTMEN1
SCHEMBL12875680 0.69 L3MBTL1 (0.44) KDM4EHPGDGAAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A NPC1 3877/4885RAB9A 2507/4885SIRT5 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.